APOC3 and metabolic syndrome: Unlike the contradictory data from the LPL activator, abrogating the inhibitory effects of ApoC3 and ANGPTLs on LPL activity consistently reduces circulating TG levels, thus yielding promising outcomes of dyslipidemia in different experimental animal models (4).